CorMedix Inc. Presents Data Demonstrating Antimicrobial Activity of Taurolidine Against Potentially Deadly Fungal Pathogen Candida auris
Poster Presented at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
Bedminster, NJ – September 7, 2017 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that a poster titled, “Multi-Resistant Candida Auris is Susceptible to Taurolidine,” was presented at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance held September 6–8, 2017, in Boston, MA. The study concluded that taurolidine has reproducible antimicrobial activity against each of the 20 clinical isolates of multi-resistant Candida auris that were tested.
Bruce Reidenberg, M.D., Lead Author and Adjunct Assistant Professor of Pharmacology at Weill Cornell Medicine stated, “I’m excited to present the results of sensitivity testing of taurolidine vs. C. auris to this prestigious international conference. This fungus is an emerging health threat and a focus of concern in acute care hospital settings in many countries. Our data highlight Taurolidine’s anti-fungal activity in addition to its well-known antibacterial activity. The broad spectrum in vitro results indicate important uses for Taurolidine in addition to its use in Neutrolin®, such as in sutures, surgical meshes and hydrogels, for many indications such as wound closure, burns or diabetic foot ulcers.”
A total of 20 C. auris isolates collected from hospitalized patients between 2007 and 2011 were tested against taurolidine using the CLSI Broth Microdilution Susceptibility Method. All C. auris isolates were resistant to both Amphotericin and to Fluconazole and all were susceptible to taurolidine. The concentrations of taurolidine tested were lower than the concentration in Neutrolin®.
Khoso Baluch, CorMedix Chief Executive Officer stated, “These results are very encouraging in the context of our product candidate portfolio, as taurolidine activity against C. auris supports the clinical utility of our lead product, Neutrolin, as well as our antimicrobial medical device program. Patients at the highest risk of C. auris infection include those with central venous catheters, have undergone recent surgery, have diabetes, and have used broad-spectrum antibiotics and antifungals. C. auris often does not respond to commonly used antifungal drugs, making infections difficult to treat and highlighting the need for new, effective anti-infective products.”
About CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for 5 additional years of QIDP market exclusivity in the event of U.S. approval. Neutrolin is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes, and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. For more information, visit: www.cormedix.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to possible uses of taurolidine, that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: preclinical results are not indicative of success in clinical trials and might not be replicated in any subsequent studies or trials; the risks and uncertainties associated with CorMedix’s ability to manage its limited cash resources and the impact on planned or future research, including for additional uses for taurolidine; the possible inability to capture sufficient CRBSI events in the ongoing Phase 3 clinical trial for Neutrolin® even with the reported changes to that trial; the cost, timing and results of the ongoing and planned Phase 3 trials for Neutrolin® in the U.S. and the resources needed to commence and complete those trials; obtaining additional financing to support CorMedix’s research and development and clinical activities and operations; and the ability to retain and hire necessary personnel to staff our operations appropriately. These and other risks are described in greater detail in CorMedix’s filings with the SEC, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
For Investors & Media:
Tiberend Strategic Advisors, Inc.